1700008F21Rik Activators are a diverse array of chemical compounds that enhance the functional activity of 1700008F21Rik through various indirect mechanisms. Forskolin and IBMX both elevate intracellular levels of cyclic nucleotides, cAMP, and cGMP, respectively. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate proteins that interact with or are part of the functional processes of 1700008F21Rik, resulting in its activity enhancement. Similarly, PMA activates PKC, which phosphorylates target proteins in the signaling pathways involving 1700008F21Rik, leading to its indirect activation. Sphingosine-1-phosphate triggers a signaling cascade that enhances cellular processes1700008F21Rik Activators are a diverse array of chemical compounds that enhance the functional activity of 1700008F21Rik through various indirect mechanisms. Forskolin and IBMX both elevate intracellular levels of cyclic nucleotides, cAMP, and cGMP, respectively. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate proteins that interact with or are part of the functional processes of 1700008F21Rik, resulting in its activity enhancement.
Similarly, PMA activates PKC, which phosphorylates target proteins in the signaling pathways involving 1700008F21Rik, leading to its indirect activation. Sphingosine-1-phosphate triggers a signaling cascade that enhances cellular processes in which 1700008F21Rik may be involved, leading to its functional activation. Epigallocatechin gallate, through kinase inhibition, can reduce competitive signaling, thereby enhancing pathways that 1700008F21Rik is involved in, and Genistein, by inhibiting tyrosine kinases, could similarly streamline signaling to favor 1700008F21Rik's role in the cell. The use of PI3K inhibitors LY294002 and Wortmannin can lead to a reduction in the competing PI3K/AKT pathway signaling, potentially causing a shift that favors the activation of 1700008F21Rik through alternative routes. Inhibitors of MAPK signaling, SB203580 and U0126, by selectively inhibiting p38 and MEK1/2, respectively, can also indirectly promote the activation of 1700008F21Rik by allowing the cell to redirect signaling efforts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevent the breakdown of cAMP and cGMP. This leads to increased levels of these cyclic nucleotides, indirectly enhancing the signaling pathways that 1700008F21Rik is involved in. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts on its receptors to initiate a signaling cascade that promotes cellular proliferation and survival, which are processes that 1700008F21Rik may be involved in, leading to its indirect functional enhancement. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate inhibits various protein kinases, which could decrease competitive signaling pathways and indirectly enhance the signaling pathway specificity of 1700008F21Rik, leading to its functional activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, altering the PI3K/AKT pathway. By inhibiting this pathway, there could be a shift in signaling that indirectly enhances the activation of 1700008F21Rik through compensatory pathways or processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which similarly to LY294002, can modify the PI3K/AKT signaling. This leads to an indirect enhancement of the signaling pathways that are relevant to the function of 1700008F21Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. By inhibiting p38, it may result in the enhancement of alternative signaling pathways or cellular processes that indirectly increase the functional activity of 1700008F21Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore, which increases intracellular calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, which could indirectly enhance the signaling processes involving 1700008F21Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor which leads to an increase in cytosolic calcium levels. This can potentially enhance calcium-dependent signaling pathways that indirectly activate the functional processes of 1700008F21Rik. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, which may lead to reduced competition in tyrosine kinase-dependent signaling pathways. This can indirectly enhance the pathways and cellular processes that 1700008F21Rik is involved in. | ||||||